CN106580966A - 一种组合物在制备治疗脑震荡的药物中的应用 - Google Patents
一种组合物在制备治疗脑震荡的药物中的应用 Download PDFInfo
- Publication number
- CN106580966A CN106580966A CN201710029034.7A CN201710029034A CN106580966A CN 106580966 A CN106580966 A CN 106580966A CN 201710029034 A CN201710029034 A CN 201710029034A CN 106580966 A CN106580966 A CN 106580966A
- Authority
- CN
- China
- Prior art keywords
- compositionss
- edaravone
- concussion
- cerebral concussion
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 229940079593 drug Drugs 0.000 title claims abstract description 9
- 239000000203 mixture Substances 0.000 title abstract description 9
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 206010010254 Concussion Diseases 0.000 title abstract 2
- 230000009514 concussion Effects 0.000 title abstract 2
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 claims abstract description 45
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 208000007333 Brain Concussion Diseases 0.000 claims description 43
- 241000700159 Rattus Species 0.000 claims description 14
- 230000008499 blood brain barrier function Effects 0.000 claims description 11
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 11
- 206010030113 Oedema Diseases 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- FXXMNCZOYVUJEE-UHFFFAOYSA-N C1(=CC=CC=C1)N1N=CCC1=O.CC1(CC(C(=O)O)=CC=C1)C(=O)O Chemical class C1(=CC=CC=C1)N1N=CCC1=O.CC1(CC(C(=O)O)=CC=C1)C(=O)O FXXMNCZOYVUJEE-UHFFFAOYSA-N 0.000 claims 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract description 8
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract description 8
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract description 6
- 229940116229 borneol Drugs 0.000 abstract description 6
- 229950009041 edaravone Drugs 0.000 description 30
- 210000004556 brain Anatomy 0.000 description 10
- 230000002490 cerebral effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 7
- 230000035699 permeability Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 208000024806 Brain atrophy Diseases 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DTGKSKDOIYIVQL-MRTMQBJTSA-N Isoborneol Natural products C1C[C@@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-MRTMQBJTSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000000185 intracerebroventricular administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 201000008247 brain infarction Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical group NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- -1 nitric oxide free radical Chemical class 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-M peroxynitrite Chemical compound [O-]ON=O CMFNMSMUKZHDEY-UHFFFAOYSA-M 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710029034.7A CN106580966A (zh) | 2017-01-16 | 2017-01-16 | 一种组合物在制备治疗脑震荡的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710029034.7A CN106580966A (zh) | 2017-01-16 | 2017-01-16 | 一种组合物在制备治疗脑震荡的药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106580966A true CN106580966A (zh) | 2017-04-26 |
Family
ID=58584855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710029034.7A Pending CN106580966A (zh) | 2017-01-16 | 2017-01-16 | 一种组合物在制备治疗脑震荡的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106580966A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101848711A (zh) * | 2008-03-04 | 2010-09-29 | 江苏先声药物研究有限公司 | 一种药物组合物及其在制备治疗脑血管病药物中的应用 |
WO2012009204A1 (en) * | 2010-07-15 | 2012-01-19 | The Trustees Of Columbia University In The City Of New York | Methods for diagnosing and treating concussive disorders |
-
2017
- 2017-01-16 CN CN201710029034.7A patent/CN106580966A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101848711A (zh) * | 2008-03-04 | 2010-09-29 | 江苏先声药物研究有限公司 | 一种药物组合物及其在制备治疗脑血管病药物中的应用 |
WO2012009204A1 (en) * | 2010-07-15 | 2012-01-19 | The Trustees Of Columbia University In The City Of New York | Methods for diagnosing and treating concussive disorders |
Non-Patent Citations (1)
Title |
---|
漆平芳等: "依达拉奉治疗脑震荡临床疗效分析", 《宜春学院学报》, vol. 34, no. 8, 31 August 2012 (2012-08-31), pages 96 - 97 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3485885A1 (en) | Compound and method for treatment of diseases and disorders | |
AU2017223838B2 (en) | Treatment of neurodegenerative eye disease using pridopidine | |
EP2385835B1 (de) | Verwendung von deuteriumoxid zur behandlung viraler erkrankungen des auges | |
KR20160079132A (ko) | 치매를 예방하고/하거나 치료하기 위한 약물의 제조에서의 진세노사이드-rg3의 용도 및 약물 | |
KR20140072819A (ko) | 포스포디에스테라제 타입 5 저해제를 포함하는 신경세포의 아폽토시스 억제용 조성물 | |
Zhu et al. | Oral scutellarin treatment ameliorates retinal thinning and visual deficits in experimental glaucoma | |
CN105106318B (zh) | 一种治疗干眼症的中药组合物及其制备方法 | |
KR20180100152A (ko) | 비알코올성 지방간 질환의 치료 또는 예방용 의약의 제조에서의 트리아세틸-3-하이드록시페닐아데노신의 용도 | |
RU2431496C2 (ru) | Инъекционная лекарственная форма для лечения острого ишемического инсульта и черепно-мозговой травмы, способ ее изготовления и применение | |
BR112013002084A2 (pt) | método de tratamento de condição bronco-constritiva | |
CN106580966A (zh) | 一种组合物在制备治疗脑震荡的药物中的应用 | |
CN103417522A (zh) | L-丝氨酸在制备治疗脑损伤、神经组织损伤的药物中的应用 | |
RU2689384C1 (ru) | Применение холиновой соли янтарной кислоты в производстве средств лечения черепно-мозговой травмы | |
CN112043700B (zh) | 盐酸去亚甲基四氢小檗碱在制备预防或治疗神经退行性疾病药物中的应用 | |
CN104473932B (zh) | 治疗中枢神经系统炎症性脱髓鞘疾病的药物组合物及其联合给药的用途 | |
CA2941606C (en) | Kits and methods for treating post traumatic stress disorder (ptsd) and hot flashes | |
US20220288016A1 (en) | Compositions and methods for the treatment or prevention of traumatic brain injury | |
EP4188364A1 (en) | Methods for maintaining microvascular integrity | |
CN108578397A (zh) | 氟芬那酸在治疗脊髓损伤中的用途 | |
CN105412078B (zh) | 丁苯酞或其衍生在制备治疗或预防脑震荡的药物中的应用 | |
CN101732713A (zh) | 抗nogo-a抗体和银杏叶提取物治疗脑中风 | |
CN104224817A (zh) | 人参二醇皂苷组分的抗精神分裂症医药用途 | |
US20190167724A1 (en) | Neuroprotective composition, preparation process thereof and medical uses thereof | |
CN111905011A (zh) | 一种抗病毒组合物与制剂及其制备方法和应用 | |
CN106309974A (zh) | 中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180523 Address after: 211800 8 Xing Long Road, Pukou Economic Development Zone, Nanjing, Jiangsu. Applicant after: NANJING SIMCERE DONGYUAN PHARMACEUTICA Co.,Ltd. Applicant after: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. Address before: 210042 699 Xuanwu Road, Xuanwu District, Nanjing, Jiangsu -18 Applicant before: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: No.99, Huakang Road, Jiangbei new district, Nanjing, Jiangsu Province, 210032 Applicant after: SIMCERE PHARMACEUTICAL Co.,Ltd. Applicant after: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. Address before: 211800 Nanjing, Pukou Economic Development Zone, Jiangsu Road, No. 8 Applicant before: NANJING SIMCERE DONGYUAN PHARMACEUTICA Co.,Ltd. Applicant before: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. |
|
CB02 | Change of applicant information | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170426 |
|
RJ01 | Rejection of invention patent application after publication |